Coley Pharmaceutical Group

Coley Pharmaceutical Group is a biopharmaceutical company that focuses on developing therapeutics and drug candidates to harness the human immune system in combating a range of ailments including cancers, asthma, allergies, and autoimmune disorders, as well as enhancing vaccine efficacy. Originally known as CpG ImmunoPharmaceuticals, Inc., the company rebranded to Coley Pharmaceutical Group, Inc. in August 2000. Founded in 1997 and with its headquarters in Wellesley, Massachusetts, the company later became a subsidiary of Pfizer Inc. on December 28, 2007. The last investment, a Post-IPO Equity investment, was made on 01 February 2007 by Thuja Capital. The company's slogan encapsulates its core mission, which is to empower the immune system to conquer illnesses and boost vaccine efficacy. With a focus on Biotechnology and Health Care industries, Coley Pharmaceutical Group continues to make strides in the field of immunotherapy and biopharmaceuticals.